World’s First AI Rapid Antigen Test System for COVID-19 Delivers Highly Accurate Results on Smartphone Within 5-8 Minutes

The world’s first rapid COVID-19 antigen test system using artificial intelligence (AI) could revolutionize medical diagnostics, enabling early disease detection with consistent and accurate results.

Laipac Technology Inc. (Ontario, Canada), a developer of IoMT (Internet of Medical Things), has entered into a partnership with YAS Pharmaceuticals LLC (Abu Dhabi, UAE) and Pure Health LLC (Dubai, UAE) to launch the European CE-IVD approved LooK SPOT AI COVID-19 Antigen Rapid Test System.

The LooK SPOT solution is an intelligent and innovative way to deploy technologies to better protect the health of people across the region. Being able to have a quick and accurate COVID-19 diagnosis can interrupt transmission, aid clinical management, and help proper allocation of resources to isolation. The smartphone-based diagnostic device with lateral flow immunoassay is intended for the qualitative detection of nucleocapsid protein from SARS-CoV-2 in nasal swabs. The LooK SPOT Artificial Intelligence Ecosystem revolutionizes medical diagnostics, enabling early disease detection with consistent and accurate results.

LooK SPOT AI COVID-19 Antigen Rapid Test uses the nasal sample collected from one inch in the nostril. It uses AI technology to deliver real-time test results within 5 to 8 minutes with 97.4% sensitivity and 98.3% specificity in detecting the SARS-CoV-2 virus. The LooK SPOT COVID-19 Antigen Rapid Test can also detect the new variant of the SARS-CoV-2 virus which was first identified in the UK and South Africa.

The LooK PASS App can be downloaded from Apple or Google stores, to scan the LooK COVID-19 antigen cassette before the test, and test results can be received on smartphones within 5 to 8 minutes. Negative test results generate a QR code on the app which may be used as a pass to enter a facility, events and gatherings or used for transport facilities. Via Pure Health, LooK SPOT will be able to provide a full API integration with multiple IT applications and travel applications for real time reporting.

"LooK SPOT's AI Algorithm has high accuracy and can identify the color signal on tests in low positive cases when human eyes cannot, therefore eliminating the human error and manual process done with other antigen tests available in the market. LooK SPOT reduces healthcare responders' cognitive load by providing accurate test results in an easy-to-read format. LooK SPOT has been designed with a tactical edge to fight COVID-19," said Diego Lai, Co-founder and CEO of Laipac.

Related Links:
Laipac Technology Inc.
YAS Pharmaceuticals LLC
Pure Health LLC